Online citations, reference lists, and bibliographies.

Low Rate Of Intraperitoneal Port Placement In Ovarian Cancer Patients, A Population-based Assessment

L. Buckingham, A. Koenig, E. Ko, C. Brensinger, N. Latif, C. Hummel, X. Zhang, M. Morgan, R. Burger, Robert L Giuntoli Ii
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Introduction The National Comprehensive Cancer Network (NCCN) guidelines recommend intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients. The objective of this investigation was to determine the rate of intraperitoneal port placement in patients undergoing surgery for ovarian cancer in a national database maintained by the American College of Surgeons. Method We identified ovarian cancer patients in the National Surgical Quality Improvement Program database from 2006 to 2012. Demographics, comorbidities, operative outcomes, and postoperative complications were abstracted. Descriptive analyses were conducted using Wilcoxon rank-sum and Chi square tests, and multivariate regression models were used to analyze pre-operative and post-operative variables associated with intraperitoneal port placement. Results We identified 2659 ovarian cancer patients who underwent primary surgical management. Of these patients, only 128 (4.8%) had an intraperitoneal port placed at the time of surgery. In multivariable analyses, intraperitoneal ports were associated with body mass index ≤25, disseminated cancer, later portion of the study period (2009–2012), and operative time >200 min. Intraperitoneal port placement was not associated with any difference in surgical site infection, wound disruption, major postoperative complication, readmission within 30 days, or death within 30 days. Discussion Recent investigation of practice at NCCN institutions between 2003 and 2012 found only 35% of eligible ovarian cancer patients received intraperitoneal chemotherapy. Using intraperitoneal port placement as a surrogate for intraperitoneal chemotherapy administration, our investigation suggests an even lower rate (4.8%) nationally.
This paper references
A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma a GOG/NRG trial (GOG 252)
JL Walker (2016)
Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography.
I. Rutten (2016)
Carcinoma of the Ovary.
A. Heintz (2006)
Cancer of the ovary.
M. McKay (1994)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr
M. Markman (2001)
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Joseph J. Ivy (2009)
Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study
Mathieu Luyckx (2012)
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
A. Du Bois (2009)
Cancer statistics, 2017
R. Siegel (2017)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
D. Armstrong (2006)
Does Surgical Quality Improve in the American College of Surgeons National Surgical Quality Improvement Program: An Evaluation of All Participating Hospitals
B. Hall (2009)
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
J. N. Barlin (2012)
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.
R. Dedrick (1997)
Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer
Gema Bruixola (2015)
Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
Jo Marie Tran Janco (2011)
The patient safety in surgery study: background, study design, and patient populations.
S. Khuri (2007)
Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data
S. Polterauer (2012)
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
T. Hellevik (2014)
Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
R. W. Naumann (2009)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
J. Walker (2006)
The if and when of surgical debulking for ovarian carcinoma.
T. Thigpen (2004)
It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.
Melissa S. Henretta (2011)
Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Kathleen M. Fairfield (2014)
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
L. Landrum (2008)
A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study
J. Walker (2016)
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
A. Heintz (2006)
A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma a GOG/NRG trial
J L Walker
Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical Recommendation
Erin J. Aiello Bowles (2014)
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
J. Walker (2019)
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
D. Chi (2009)
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D. Alberts (1996)
Intraperitoneal chemotherapy in ovarian cancer.
L. Hofstra (2000)
Comparison of Morbidity and Survival Between Primary and Interval Cytoreductive Surgery in Patients After Modified Posterior Pelvic Exenteration for Advanced Ovarian Cancer
A. Revaux (2012)
User guide for the 2012 ACS NSQIP participant use data file
Surgeons Aco (2013)
Review: Practical considerations in ovarian cancer chemotherapy
M. Cristea (2010)
Cancer statistics
N. Dubrawsky (1989)
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
A. Wright (2015)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar